Protein Kinase A (PKA), also known as cAMP-dependent protein kinase, is a crucial serine/threonine kinase that mediates numerous cellular signaling pathways in neurons. PKA is particularly important in dopaminergic neurons of the substantia nigra pars compacta (SNc) and striatum, where it regulates movement control, reward processing, and synaptic plasticity. Dysregulation of PKA signaling is implicated in several neurodegenerative diseases, most notably Parkinson's disease (PD) and Huntington's disease (HD), making it a significant therapeutic target. [1]
This page provides a comprehensive examination of PKA-expressing neurons in the central nervous system, focusing on their molecular mechanisms, electrophysiological properties, and disease relevance.
PKA is a heterotetrameric enzyme consisting of two regulatory (R) subunits and two catalytic (C) subunits. The regulatory subunits bind and inhibit the catalytic subunits in the absence of cyclic AMP (cAMP), maintaining the enzyme in an inactive state. Upon cAMP binding, the regulatory subunits undergo conformational changes, releasing the catalytic subunits to phosphorylate downstream substrates. [2]
The PKA family comprises multiple isoforms:
This diversity allows for tissue-specific expression and distinct subcellular localization. In the brain, R1α and R2β are the predominant regulatory subunit isoforms, while Cα and Cβ are the main catalytic subunits. [3]
A critical feature of PKA signaling is its localization through A-Kinase Anchoring Proteins (AKAPs). AKAPs are a diverse family of scaffolding proteins that tether PKA to specific subcellular compartments, bringing the kinase into proximity with its relevant substrates and regulatory proteins. This spatial organization ensures specificity in PKA signaling and allows for precise temporal control of phosphorylation events. [4]
Dopamine receptors belong to two distinct families based on their signaling mechanisms:
D1-like receptors (D1R, D5R) couple to Gs/olf proteins, stimulating adenylate cyclase and increasing intracellular cAMP levels. This leads to PKA activation. D1 receptors are expressed abundantly in the striatum (medium spiny neurons of the direct pathway), olfactory bulb, and prefrontal cortex.
D2-like receptors (D2R, D3R, D4R) couple to Gi/o proteins, inhibiting adenylate cyclase and reducing cAMP levels. These receptors are expressed in striatal medium spiny neurons of the indirect pathway, substantia nigra pars compacta dopamine neurons, and the pituitary gland. [5]
Dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) is a key downstream effector of dopamine receptor signaling. This protein acts as a molecular switch in striatal medium spiny neurons, integrating dopaminergic and glutamatergic signals to regulate the activity of protein phosphatase-1 (PP1). [4:1]
When phosphorylated at threonine-34 (T34) by PKA, DARPP-32 becomes a potent inhibitor of PP1. This inhibition enhances the phosphorylation state of numerous downstream substrates, including AMPA and NMDA receptor subunits, as well as transcription factors like CREB. Conversely, when phosphorylated at threonine-75 (T75) by Cdk5, DARPP-32 inhibits PKA activity, creating a negative feedback loop. [6]
PKA phosphorylates numerous substrates in neurons:
| Substrate | Site | Functional Effect |
|---|---|---|
| DARPP-32 | T34 | PP1 inhibition |
| GluA1 (AMPA) | S845 | Enhanced channel conductance |
| NR1 (NMDA) | S897 | Modulation of channel activity |
| CREB | S133 | Gene transcription |
| Tyrosine hydroxylase | S31, S40 | Increased enzyme activity |
| Phospholamban | S16 | Calcium handling regulation |
| HCN channels | S645 | Modulation ofpacemaker current |
| Kv4.2 channels | S516 | Regulation of A-current |
The striatum contains the highest density of PKA-expressing neurons in the brain. Medium spiny neurons (MSNs) in both the direct and indirect pathways show robust PKA activity, though the downstream effects differ based on dopamine receptor expression. D1-expressing MSNs in the direct pathway utilize PKA to enhance movement, while D2-expressing MSNs in the indirect pathway use PKA inhibition to suppress movement. [7]
Dopaminergic neurons in the SNc express high levels of PKA, which is critical for their survival and function. These neurons receive inhibitory input from the striatum via the direct pathway and excitatory glutamatergic input from the subthalamic nucleus. PKA signaling in SNc neurons regulates:
PKA is enriched in hippocampal CA1 and CA3 pyramidal neurons, where it plays essential roles in synaptic plasticity. Long-term potentiation (LTP) and long-term depression (LTD) in the hippocampus require PKA activity for their induction and maintenance. PKA phosphorylates AMPA receptor subunits, NMDA receptors, and transcription factors like CREB to consolidate synaptic changes. [8]
Cortical pyramidal neurons express PKA, particularly in layers 2/3 and 5. In these neurons, PKA modulates:
In the cerebellum, PKA is highly expressed in Purkinje cells and granule cells. PKA signaling in Purkinje cells regulates synaptic plasticity at parallel fiber-Purkinje cell synapses and climbing fiber-Purkinje cell synapses, which are critical for motor learning.
The locus coeruleus (LC) contains noradrenergic neurons that project throughout the brain. These neurons express PKA, which mediates the effects of norepinephrine on arousal, attention, and sleep-wake cycles. PKA in LC neurons regulates:
PKA phosphorylates numerous ion channels to modulate neuronal excitability:
HCN channels: Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are modulated by PKA phosphorylation, which shifts the activation curve to more depolarized potentials and increases the funny current (If). This enhances neuronal pacemaker activity in dopaminergic neurons. [9]
Kv4.2 channels: PKA phosphorylation of Kv4.2 channels reduces the A-current, increasing neuronal excitability in striatal neurons.
NMDA receptors: PKA phosphorylation of the NR1 subunit at serine-897 enhances channel activity, facilitating calcium influx and subsequent signaling events.
PKA is a critical regulator of both LTP and LTD:
Long-term Potentiation (LTP): PKA is required for the induction of LTP in many brain regions. By phosphorylating AMPA receptor subunits (particularly GluA1 at S845), PKA increases the single-channel conductance and promotes insertion of new AMPA receptors into the postsynaptic membrane. [10]
Long-term Depression (LTD): PKA also participates in LTD, though its role is more complex and often involves priming events that enable subsequent depotentiation.
PKA signaling is profoundly altered in Parkinson's disease. The loss of dopaminergic neurons in the SNc leads to reduced striatal dopamine, causing:
These changes contribute to the motor symptoms of PD, including bradykinesia, rigidity, and tremor. [11]
Chronic L-DOPA treatment, the gold standard for Parkinson's disease therapy, leads to the development of dyskinesias in most patients after 5-10 years. These abnormal involuntary movements are associated with hyperactive PKA signaling in striatal neurons:
D1 receptor hypersensitivity: Chronic L-DOPA causes upregulation of D1 receptors, leading to excessive cAMP production and PKA activation.
DARPP-32 dysregulation: Abnormal phosphorylation of DARPP-32 at both T34 and T75 disrupts the PP1 inhibition balance.
ERK and mTOR activation: PKA signaling cross-talks with MAPK and mTOR pathways, leading to abnormal gene expression and protein synthesis.
Abnormal AMPA receptor trafficking: PKA hyperphosphorylation of GluA1 S845 leads to constitutive AMPA receptor insertion. [12]
Several strategies target PKA signaling to treat dyskinesia:
PKA signaling is altered in Huntington's disease, a neurodegenerative disorder caused by mutant huntingtin protein expansion. Studies show:
These changes contribute to striatal neuron vulnerability and motor symptoms. [15]
PKA signaling is implicated in schizophrenia through its role in dopamine receptor signaling:
PKA plays a central role in the rewarding effects of drugs of abuse and the development of addiction:
| Compound | Mechanism | Clinical Status |
|---|---|---|
| H-89 | ATP-competitive inhibitor | Research use only |
| Rp-cAMPS | cAMP analog, competitive | Research use only |
| KT5720 | ATP-competitive inhibitor | Research use only |
These compounds are useful in research but have limited therapeutic potential due to lack of specificity and poor brain penetration.
Adenylate cyclase inhibitors: Reduce cAMP production
Phosphodiesterase (PDE) inhibitors: Increase cAMP/PDE activity
PDE10A specifically: Expressed almost exclusively in striatal medium spiny neurons, making it an attractive target for modulating PKA activity in this region without affecting other brain areas. [18]
Phospho-PKA substrate antibodies: Antibodies that recognize the phosphorylated consensus sequence RRXS*/T* enable visualization of global PKA activity.
PKA activity assays: In vitro kinase assays using synthetic substrates measure enzyme activity in tissue samples.
cAMP measurements: ELISA or HPLC methods quantify intracellular cAMP levels.
FRET sensors: Genetically encoded cAMP sensors allow real-time visualization of cAMP dynamics in living cells.
Greengard P. The neurobiology of dopamine signaling. Biological Psychiatry. 2001. ↩︎
Nairn AC, Hemmings HC, Greengard P. Protein kinases and phosphatases in the nervous system. Biochimica et Biophysica Acta. 2004. ↩︎
Huang H, Rane C, Kouser A, Feher K, Zhou J, et al. Genetic depletion of the protein kinase A catalytic subunit in mice does not affect viability but alters circadian rhythm. Journal of Biological Rhythms. 2017. ↩︎
Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P. DARPP-32: a molecular switch in dopamine signaling. Annual Review of Neuroscience. 2004. ↩︎ ↩︎
Gerfen CR, Surmeier DJ. Modulation of striatal projection signaling by receptor subtypes. Journal of Neural Transmission. 2011. ↩︎
Schmitt O, Pak A, Eisel UL. Dysregulated DARPP-32 and its downstream signaling in neurodegenerative diseases. Neurobiology of Disease. 2022. ↩︎
Calabresi P, Gubellini P, Picconi B, Centonze D, Pisani A. Inhibition of mTOR-kinase antagonizes neostriatal damage induced by enzyme inhibition. Brain Research. 2007. ↩︎
Huang YY, Kandel ER. cAMP response element-mediated transcription is regulated by calcium but not by the cAMP-induced cascade in hippocampal neurons. Journal of Neuroscience. 2001. ↩︎
Ibanez-Sandoval O, Onyimbo A, Tepper JM, Koós T. Electrophysiological and morphological characteristics of striatal fast-spiking interneurons. Journal of Neurophysiology. 2011. ↩︎
Birnbaum SG, Yuan PX, Blenis J, Greengard P, Nguyen PV. Structure and function of the NMDA receptor and CaMKII in synaptic plasticity and memory. Learning & Memory. 2004. ↩︎
Girault JA, Herve D. Dopamine signaling and l-DOPA-induced dyskinesia in Parkinson's disease. Movement Disorders. 2012. ↩︎
Santini E, Valjent E, Fisone G. Dysregulation of signal transduction pathways as a biological marker of l-DOPA-induced dyskinesia. Parkinson's Disease. 2010. ↩︎
Schenone M, Ramachandran C, Ji F, Fecik R, Wang J, Almo SC, et al. Kinome-wide RNA interference screen reveals a role for PDK1 in L-DOPA-induced dyskinesia. Journal of Neuroscience. 2016. ↩︎
Taymans JM, Van den Haute C, Baekelandt V. Distribution of phosphodiesterase 10A in the rat brain. Neuroscience. 2004. ↩︎
Picconi B, Centonze D, Håkansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P. Loss of dopaminergic stimulation abrogates the anti-parkinsonian effects of l-DOPA in 6-hydroxydopamine lesioned rats. Experimental Neurology. 2003. ↩︎
Zachariou V, Georgescu D, Kandel E, Brautigam DM, Lu Z, et al. Essential role for RGS9 in movement, reward and learning. Molecular Psychiatry. 2008. ↩︎
Saal D, Dong Y, Bonci A, Malenka RC. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron. 2003. ↩︎
Wala O, Korol S, Jin W, Nies S, Husain M, et al. Phosphodiesterase 10A deficiency in mice and humans alters dopamine signaling. Neuropsychopharmacology. 2021. ↩︎